McLean L, Lim A, Angel C, Young R, Pizzolla A, Archer S
Cancers (Basel). 2024; 16(8).
PMID: 38672534
PMC: 11048307.
DOI: 10.3390/cancers16081452.
Singh H, Chopra H, Singh I, Mohanto S, Ahmed M, Ghumra S
EXCLI J. 2024; 23:300-334.
PMID: 38655092
PMC: 11036065.
DOI: 10.17179/excli2023-6489.
Cozma E, Banciu L, Soare C, Cretoiu S
Int J Mol Sci. 2023; 24(7).
PMID: 37047618
PMC: 10095059.
DOI: 10.3390/ijms24076646.
Bossi P, Lorini L
Dermatol Pract Concept. 2021; 11(Suppl 2):e2021170S.
PMID: 34877078
PMC: 8609951.
DOI: 10.5826/dpc.11S2a170S.
Miao K, Zhang L
Interdiscip Sci. 2021; 13(4):801-814.
PMID: 34152556
DOI: 10.1007/s12539-021-00437-4.
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM).
Gonzalez-Cao M, Puertolas T, Riveiro M, Munoz-Couselo E, Ortiz C, Paredes R
J Immunother Cancer. 2021; 9(3).
PMID: 33782108
PMC: 8009216.
DOI: 10.1136/jitc-2020-001664.
Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?.
Wessely A, Steeb T, Leiter U, Garbe C, Berking C, Heppt M
Int J Mol Sci. 2020; 21(23).
PMID: 33291277
PMC: 7730197.
DOI: 10.3390/ijms21239300.
Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.
Claveau J, Archambault J, Ernst D, Giacomantonio C, Limacher J, Murray C
Curr Oncol. 2020; 27(4):e399-e407.
PMID: 32905333
PMC: 7467796.
DOI: 10.3747/co.27.6015.
Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
Trager M, Coley S, Dube G, Khan S, Ingham M, Samie F
J Immunother Cancer. 2020; 8(1).
PMID: 32503950
PMC: 7279669.
DOI: 10.1136/jitc-2020-000908.
Cutaneous Squamous Cell Carcinoma: From Biology to Therapy.
Corchado-Cobos R, Garcia-Sancha N, Gonzalez-Sarmiento R, Perez-Losada J, Canueto J
Int J Mol Sci. 2020; 21(8).
PMID: 32331425
PMC: 7216042.
DOI: 10.3390/ijms21082956.
Recent and Emerging Therapies for Cutaneous Squamous Cell Carcinomas of the Head and Neck.
Varra V, Smile T, Geiger J, Koyfman S
Curr Treat Options Oncol. 2020; 21(5):37.
PMID: 32328817
DOI: 10.1007/s11864-020-00739-7.
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V, Shinagare A, Rennke H, Ghai S, Lorch J, Ott P
Oncologist. 2020; 25(6):505-514.
PMID: 32043699
PMC: 7288631.
DOI: 10.1634/theoncologist.2019-0659.
Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients.
Manohar S, Thongprayoon C, Cheungpasitporn W, Markovic S, Herrmann S
Kidney Int Rep. 2020; 5(2):149-158.
PMID: 32043028
PMC: 7000848.
DOI: 10.1016/j.ekir.2019.11.015.
Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies.
Lima P, Joseph S, Panizza B, Simpson F
Curr Treat Options Oncol. 2020; 21(1):9.
PMID: 32016630
DOI: 10.1007/s11864-019-0697-3.
Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
Liu Y, Fitzgerald B, Perry E, Pathak A, Chao H
J Investig Med High Impact Case Rep. 2019; 7:2324709619850216.
PMID: 31132886
PMC: 6540500.
DOI: 10.1177/2324709619850216.
Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?.
Lai H, Lin J, Hwang T, Liu Y, Yang A, Wu C
Int J Mol Sci. 2019; 20(9).
PMID: 31058839
PMC: 6540260.
DOI: 10.3390/ijms20092194.
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.
Abdel-Wahab N, Safa H, Abudayyeh A, Johnson D, Trinh V, Zobniw C
J Immunother Cancer. 2019; 7(1):106.
PMID: 30992053
PMC: 6469201.
DOI: 10.1186/s40425-019-0585-1.
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.
Tio M, Rai R, Ezeoke O, McQuade J, Zimmer L, Khoo C
Eur J Cancer. 2018; 104:137-144.
PMID: 30347289
PMC: 10176037.
DOI: 10.1016/j.ejca.2018.09.017.
Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research.
Gassmann D, Weiler S, Mertens J, Reiner C, Vrugt B, Nageli M
Transplant Direct. 2018; 4(8):e376.
PMID: 30255136
PMC: 6092180.
DOI: 10.1097/TXD.0000000000000814.
Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma.
Abikhair Burgo M, Roudiani N, Chen J, Santana A, Doudican N, Proby C
JCI Insight. 2018; 3(17).
PMID: 30185657
PMC: 6171807.
DOI: 10.1172/jci.insight.120750.
